This database contains 31 studies, archived under the term: "huntington disease"
Click here to filter this large number of results.
Voxel-based morphometry in individual patients: a pilot study in early Huntington disease
Mühlau, M.,
Wohlschläger, A. M.,
Gaser, C.,
Valet, M.,
Weindl, A.,
Nunnemann, S.,
Peinemann, A.,
Etgen, T.,
Ilg, R.
Background and Purpose: Voxel-based morphometry (VBM) has proved a powerful method to detect subtle changes of gray matter (GM) at the group level but the role of VBM for the detection of GM changes in single subjects, especially in those with suspected neurodegenerative disorder, remains uncertain. Here, we performed single subject analyses in 22 patients […]
A pilot study using nabilone for symptomatic treatment in Huntington’s disease
Pilot study of nabilone in Huntington’s disease (HD). Double-blind, placebo-controlled, cross-over study of nabilone versus placebo. Primary outcome, Unified Huntington’s Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = […]
Treatment of the symptoms of Huntington’s disease: preliminary results comparing aripiprazole and tetrabenazine
Brusa, Livia,
Orlacchio, Antonio,
Moschella, Vincenzo,
Iani, Cesare,
Bernardi, Giorgio,
Mercuri, Nicola Biagio
Aripiprazole (AP), a dopamine (DA) D(2) receptor partial agonist, has recently been used to reduce schizophrenic symptoms, while tetrabenazine (TBZ), a DA depletor, has been used to treat hyperkinesias in Huntington’s disease (HD). The aim of this study is to define the role of AP on chorea, motor performance, and functional disability, and to compare […]
Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease
Beglinger, Leigh J.,
Adams, Williams H.,
Paulson, Henry,
Fiedorowicz, Jess G.,
Langbehn, Douglas R.,
Duff, Kevin,
Leserman, Anne,
Paulsen, Jane S.
Background: Cognitive symptoms are associated with functional disability in Huntington disease; yet, few controlled trials have examined cognitive treatments that could improve patient independence and quality of life. Atomoxetine is a norepinephrine reuptake inhibitor approved for treatment of attention-deficit/hyperactivity disorder.; Methods: Twenty participants with mild Huntington disease who complained of inattention were randomized to receive […]
A randomized, placebo-controlled trial of latrepirdine in Huntington disease
Kieburtz, Karl,
McDermott, Michael P.,
Voss, Tiffini S.,
Corey-Bloom, Jody,
Deuel, Lisa M.,
Dorsey, E. Ray,
Factor, Stewart,
Geschwind, Michael D.,
Hodgeman, Karen,
Kayson, Elise,
Noonberg, Sarah,
Pourfar, Michael,
Rabinowitz, Karen,
Ravina, Bernard,
Sanchez-Ramos, Juan,
Seely, Lynn,
Walker, Francis,
Feigin, Andrew
Objectives: To evaluate the safety and tolerability of latrepirdine in Huntington disease (HD) and explore its effects on cognition, behavior, and motor symptoms.; Design: Double-blind, randomized, placebo-controlled trial.; Setting: Multicenter outpatient trial.; Participants: Ninety-one participants with mild to moderate HD enrolled at 17 US and UK centers from July 18, 2007, through July 16, 2008.; […]
Magnetization transfer imaging in premanifest and manifest huntington disease: a 2-year follow-up
van den Bogaard, S. J. A.,
Dumas, E. M.,
Hart, E. P.,
Milles, J.,
Reilmann, R.,
Stout, J. C.,
Craufurd, D.,
Gibbard, C. R.,
Tabrizi, S. J.,
van Buchem, M. A.,
van der Grond, J.,
Roos, R. A. C.
Background and Purpose: MTI is a quantitative MR imaging technique that has recently demonstrated structural integrity differences between controls and patients with HD. Potentially, MTI can be used as a biomarker for monitoring disease progression. To establish the value of MTI as a biomarker, we aimed to examine the change in these measures during the […]
The effects of multidisciplinary rehabilitation in patients with early-to-middle-stage Huntington’s disease: a pilot study
Thompson, J. A.,
Cruickshank, T. M.,
Penailillo, L. E.,
Lee, J. W.,
Newton, R. U.,
Barker, R. A.,
Ziman, M. R.
Background and Purpose: Despite advances in the understanding of Huntington’s disease (HD), treatment remains symptomatic. Multidisciplinary rehabilitation, however, appears to impact disease progression. Here we show the feasibility, safety and efficacy of a 9-month multidisciplinary rehabilitation programme in a small cohort of patients with early-to-middle-stage HD.; Methods: Twenty patients with HD were assigned to two […]
One-year safety and tolerability profile of pridopidine in patients with Huntington disease
Squitieri, Ferdinando,
Landwehrmeyer, Bernhard,
Reilmann, Ralf,
Rosser, Anne,
de Yebenes, Justo Garcia,
Prang, Allan,
Ivkovic, Jelena,
Bright, Jeremy,
Rembratt, Åsa
Objective: To assess the 1-year safety profile of the dopaminergic stabilizer pridopidine in patients with Huntington disease. Methods: Patients received pridopidine 45 mg/day for 4 weeks then pridopidine 90 mg/day for 22 weeks in this 6-month open-label extension (OLE) of the 6-month MermaiHD randomized controlled trial (RCT). Any adverse events (AEs) were recorded. Patients were […]